RxDoctor Payments Data

Benjamin Oke, MD

Internal Medicine · Hudson, NYNPI 1609823434

Payments from drug & device makers

$1,165in general payments, 2019–2025

Across 79 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$423
  • Pfizer$109
  • AbbVie$104
  • Amgen$89
  • Boehringer Ingelheim$79
  • Johnson & Johnson$71
  • plus $290 from 8 others

What the payments were for

  • Food & beverage$1,165100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,165 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$42,483
Medicare patients
223
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$96,413
JanuviaSitagliptin Phosphate84$85,812
EliquisApixaban81$85,531
XareltoRivaroxaban48$56,440
OzempicSemaglutide27$27,964
TrulicityDulaglutide14$21,816
FarxigaDapagliflozin Propanediol26$21,463
LinzessLinaclotide31$18,652
TradjentaLinagliptin11$16,330
EntrestoSacubitril/Valsartan37$11,878
MyrbetriqMirabegron38$11,373
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$11,363
Spiriva RespimatTiotropium Bromide20$10,402
SymbicortBudesonide/Formoterol Fumarate39$10,261
Dofetilide17$7,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$79$123,145128 claims
MerckJanuvia$39$85,81284 claims
PfizerEliquis$109$85,53181 claims
Johnson & JohnsonXarelto$71$56,44048 claims
AstraZenecaFarxiga, Symbicort$52$31,72465 claims
Novo NordiskOzempic$423$27,96427 claims
AbbVieLinzess, Restasis$104$26,01748 claims
Lilly USA, LLCTrulicity$31$21,81614 claims
NovartisEntresto$68$11,87837 claims
Astellas Pharma US IncMyrbetriq$59$11,37338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hudson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →